Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

IF 5.1 2区 医学 Q1 HEMATOLOGY
Ahmad Nanaa, Rong He, James M. Foran, Talha Badar, Naseema Gangat, Animesh Pardanani, William J. Hogan, Mark R. Litzow, Mrinal Patnaik, Aref Al-Kali, Hassan B. Alkhateeb
{"title":"Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients","authors":"Ahmad Nanaa,&nbsp;Rong He,&nbsp;James M. Foran,&nbsp;Talha Badar,&nbsp;Naseema Gangat,&nbsp;Animesh Pardanani,&nbsp;William J. Hogan,&nbsp;Mark R. Litzow,&nbsp;Mrinal Patnaik,&nbsp;Aref Al-Kali,&nbsp;Hassan B. Alkhateeb","doi":"10.1111/bjh.19105","DOIUrl":null,"url":null,"abstract":"<p>Venetoclax (VEN) is an FDA-approved selective inhibitor of B-cell leukaemia/lymphoma-2 (BCL-2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high-risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating <i>DDX41</i>-mutated (m<i>DDX41</i>) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of m<i>DDX41</i> MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"204 1","pages":"171-176"},"PeriodicalIF":5.1000,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19105","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19105","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Venetoclax (VEN) is an FDA-approved selective inhibitor of B-cell leukaemia/lymphoma-2 (BCL-2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high-risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating DDX41-mutated (mDDX41) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of mDDX41 MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach.

Abstract Image

Venetoclax 加用低甲基化药物治疗 DDX41 突变的急性髓性白血病和骨髓增生异常综合征:梅奥诊所对 12 名患者的系列研究。
Venetoclax(VEN)是美国食品及药物管理局(FDA)批准的一种B细胞白血病/淋巴瘤-2(BCL-2)选择性抑制剂,用于治疗无法接受强化化疗的老年或体质不佳的急性髓性白血病(AML)患者。在高危骨髓增生异常综合征(MDS)和复发/难治性急性髓性白血病(AML)患者中,VEN与低甲基化药物(HMAs)的联合治疗显示出令人印象深刻的应答率。然而,VEN和HMAs治疗DDX41突变(mDDX41)MDS/AML患者的疗效仍不确定。尽管mDDX41 MDS/AML患者的预后较好,但缺乏有关他们对不同治疗方案反应的临床经验,导致最佳治疗方法不明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.60
自引率
4.60%
发文量
565
审稿时长
1 months
期刊介绍: The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信